Published in Genes Dev on April 15, 1997
Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev (2001) 4.45
Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J (2002) 3.99
Elongation of the Kcnq1ot1 transcript is required for genomic imprinting of neighboring genes. Genes Dev (2006) 3.30
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci U S A (2004) 3.27
CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev (1998) 2.91
p21(CIP1) and p57(KIP2) control muscle differentiation at the myogenin step. Genes Dev (1999) 2.58
BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development (2004) 2.50
Cell cycle regulation in hematopoietic stem cells. J Cell Biol (2011) 2.48
Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A (2003) 2.45
Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development. Genes Dev (1998) 2.39
The cyclin-dependent kinase inhibitor KRP2 controls the onset of the endoreduplication cycle during Arabidopsis leaf development through inhibition of mitotic CDKA;1 kinase complexes. Plant Cell (2005) 2.29
Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev (1997) 2.25
Multiple mechanisms regulate imprinting of the mouse distal chromosome 7 gene cluster. Mol Cell Biol (1998) 2.23
Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol (2000) 2.15
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med (2015) 2.05
Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes. Genes Dev (2004) 2.00
Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol (1999) 1.93
Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle (2010) 1.74
The importance of imprinting in the human placenta. PLoS Genet (2010) 1.74
Redox control of the cell cycle in health and disease. Antioxid Redox Signal (2009) 1.72
Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet (2003) 1.68
Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc Natl Acad Sci U S A (1999) 1.66
Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J Virol (2003) 1.62
Two distinct mechanisms of silencing by the KvDMR1 imprinting control region. EMBO J (2007) 1.59
An imprinted gene network that controls mammalian somatic growth is down-regulated during postnatal growth deceleration in multiple organs. Am J Physiol Regul Integr Comp Physiol (2008) 1.56
Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev (1999) 1.51
Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes. Proc Natl Acad Sci U S A (1999) 1.50
Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci U S A (1998) 1.49
Cell cycle and apoptosis. Neoplasia (2001) 1.47
Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J Clin Invest (1999) 1.46
Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A (1998) 1.41
Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J (1998) 1.39
G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol (2005) 1.35
Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells. Mol Cell Biol (2009) 1.35
E Proteins and Id2 converge on p57Kip2 to regulate cell cycle in neural cells. Mol Cell Biol (2006) 1.31
p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci U S A (2003) 1.28
Periodic expression of the cyclin-dependent kinase inhibitor p57(Kip2) in trophoblast giant cells defines a G2-like gap phase of the endocycle. Mol Biol Cell (2000) 1.28
Cardiovascular development and the colonizing cardiac neural crest lineage. ScientificWorldJournal (2007) 1.26
C/EBPbeta Promotes transition from proliferation to hypertrophic differentiation of chondrocytes through transactivation of p57. PLoS One (2009) 1.23
PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood (2011) 1.21
Roles for genomic imprinting and the zygotic genome in placental development. Proc Natl Acad Sci U S A (2001) 1.19
The imprinted Phlda2 gene regulates extraembryonic energy stores. Mol Cell Biol (2010) 1.18
Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7. BMC Dev Biol (2007) 1.17
Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol (1998) 1.17
p57(Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts. Mol Cell Biol (1999) 1.16
Arginylation-dependent neural crest cell migration is essential for mouse development. PLoS Genet (2010) 1.16
Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol Cell Biol (1998) 1.15
Bone morphogenetic protein 2-induced osteoblast differentiation requires Smad-mediated down-regulation of Cdk6. Mol Cell Biol (2004) 1.15
Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal (2012) 1.14
PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett (2008) 1.14
A cell-autonomous requirement for Cip/Kip cyclin-kinase inhibitors in regulating neuronal cell cycle exit but not differentiation in the developing spinal cord. Dev Biol (2006) 1.13
CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle (2012) 1.12
The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress. EMBO J (2012) 1.12
Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol (2010) 1.11
Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci U S A (2002) 1.11
Disruption of a novel imprinted zinc-finger gene, ZNF215, in Beckwith-Wiedemann syndrome. Am J Hum Genet (2000) 1.10
An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol (2001) 1.09
Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. Am J Pathol (2000) 1.07
MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity. Mol Cell Biol (2002) 1.07
Genetic evidence for the interactions of cyclin D1 and p27(Kip1) in mice. Mol Cell Biol (2001) 1.07
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer (2012) 1.07
Location of cell cycle regulators cyclin B1, cyclin A, PCNA, Ki67 and cell cycle inhibitors p21, p27 and p57 in human first trimester placenta and deciduas. Histochem Cell Biol (2006) 1.04
The Wnt/beta-catenin pathway interacts differentially with PTHrP signaling to control chondrocyte hypertrophy and final maturation. PLoS One (2009) 1.03
Impaired maturation of myeloid progenitors in mice lacking novel Polycomb group protein MBT-1. EMBO J (2005) 1.02
A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep (2008) 1.02
PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci U S A (2007) 1.01
Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy. Cell Div (2009) 1.01
Common and specific roles of the related CDK inhibitors p27 and p57 revealed by a knock-in mouse model. Proc Natl Acad Sci U S A (2009) 1.00
The cyclin-dependent kinase inhibitor p57(Kip2) mediates proliferative actions of PTHrP in chondrocytes. J Clin Invest (2004) 1.00
A dual function of Bcl11b/Ctip2 in hippocampal neurogenesis. EMBO J (2012) 0.99
Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A (2000) 0.99
A transgenic approach for RNA interference-based genetic screening in mice. Proc Natl Acad Sci U S A (2006) 0.99
CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle (2013) 0.99
Knockdown of cyclin-dependent kinase inhibitors induces cardiomyocyte re-entry in the cell cycle. J Biol Chem (2011) 0.99
Checkpoint kinase 1 prevents cell cycle exit linked to terminal cell differentiation. Mol Cell Biol (2011) 0.98
Induction of cellular genes is mediated by the Bel1 transactivator in foamy virus-infected human cells. J Virol (2000) 0.97
Foxp1 maintains hair follicle stem cell quiescence through regulation of Fgf18. Development (2013) 0.96
TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy. J Exp Med (2013) 0.96
Fetal overgrowth in the Cdkn1c mouse model of Beckwith-Wiedemann syndrome. Dis Model Mech (2011) 0.95
Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome. J Biol Chem (2010) 0.95
MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol Cancer (2014) 0.92
A repertoire of cell cycle regulators whose expression is coordinated with human cytotrophoblast differentiation. Am J Pathol (2000) 0.92
Increased protein stability of CDKN1C causes a gain-of-function phenotype in patients with IMAGe syndrome. PLoS One (2013) 0.91
Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation. Mol Cell Biol (2003) 0.91
Maternal-fetal conflict, genomic imprinting and mammalian vulnerabilities to cancer. Philos Trans R Soc Lond B Biol Sci (2015) 0.91
Tbx2 controls lung growth by direct repression of the cell cycle inhibitor genes Cdkn1a and Cdkn1b. PLoS Genet (2013) 0.91
Analysis of the dynamics of limb transcriptomes during mouse development. BMC Dev Biol (2011) 0.89
Cdkn1c drives muscle differentiation through a positive feedback loop with Myod. Dev Biol (2010) 0.89
Evolution of the CDKN1C-KCNQ1 imprinted domain. BMC Evol Biol (2008) 0.88
The cyclin-dependent kinase inhibitor p27(Kip1) induces N-terminal proteolytic cleavage of cyclin A. Proc Natl Acad Sci U S A (1998) 0.88
"The Octet": Eight Protein Kinases that Control Mammalian DNA Replication. Front Physiol (2012) 0.88
p16INK4a and its regulator miR-24 link senescence and chondrocyte terminal differentiation-associated matrix remodeling in osteoarthritis. Arthritis Res Ther (2014) 0.88
DNAse I pre-treatment markedly enhances detection of nuclear cyclin-dependent kinase inhibitor p57Kip2 and BrdU double immunostaining in embryonic rat brain. Histochem Cell Biol (2006) 0.87
The placental imprintome and imprinted gene function in the trophoblast glycogen cell lineage. Reprod Biomed Online (2012) 0.86
Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. World J Gastroenterol (2005) 0.85
Negative regulators of schwann cell differentiation-novel targets for peripheral nerve therapies? J Clin Immunol (2012) 0.85
p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect. Cell Death Dis (2012) 0.84
Roles of p53 in various biological aspects of hematopoietic stem cells. J Biomed Biotechnol (2012) 0.84
The role of cell differentiation in controlling cell multiplication and cancer. J Cancer Res Clin Oncol (2008) 0.83
Forced expression of the cell cycle inhibitor p57Kip2 in cardiomyocytes attenuates ischemia-reperfusion injury in the mouse heart. BMC Physiol (2008) 0.83
ras genes. Annu Rev Biochem (1987) 22.59
New use of BCG for recombinant vaccines. Nature (1991) 14.40
A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (1982) 11.92
Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem (1986) 10.00
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet (1999) 8.53
TGF beta signals through a heteromeric protein kinase receptor complex. Cell (1992) 8.12
Mechanism of activation of the TGF-beta receptor. Nature (1994) 8.10
Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (1996) 6.67
Identification of a neural stem cell in the adult mammalian central nervous system. Cell (1999) 6.53
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol (2001) 6.43
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (1986) 5.88
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature (1996) 5.21
A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev (1999) 5.13
Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (1994) 5.12
Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol (1994) 5.02
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev (1995) 4.94
To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer (2001) 4.86
GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J (1995) 4.63
T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature (1982) 4.54
The trk proto-oncogene encodes a receptor for nerve growth factor. Cell (1991) 4.54
Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature (1997) 4.41
Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature (1985) 4.40
Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (1984) 4.38
Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature (1996) 4.37
A human Mad protein acting as a BMP-regulated transcriptional activator. Nature (1996) 4.36
pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev (1997) 4.36
Cloning and expression of multiple protein kinase C cDNAs. Cell (1986) 4.23
Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol (2001) 4.22
Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med (1989) 4.20
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev (1995) 4.19
Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol (1998) 4.13
gag Gene of mammalian type-C RNA tumour viruses. Nature (1976) 4.11
Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell (1998) 3.86
Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci U S A (1986) 3.83
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell (1994) 3.74
Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature (1994) 3.73
TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol (2001) 3.69
vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J (1989) 3.67
Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev (1996) 3.61
Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell (1990) 3.61
Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature (1999) 3.59
Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem (1992) 3.57
The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell (1987) 3.52
Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell (1993) 3.51
Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev (1996) 3.49
Betaglycan presents ligand to the TGF beta signaling receptor. Cell (1993) 3.48
Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell (1999) 3.47
The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development. Nature (1993) 3.45
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature (1997) 3.29
Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science (1993) 3.28
The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev (1997) 3.28
A sperm cytoskeletal protein that signals oocyte meiotic maturation and ovulation. Science (2001) 3.26
Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem (1987) 3.25
Ubiquitin-dependent degradation of TGF-beta-activated smad2. Nat Cell Biol (1999) 3.25
The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell (1990) 3.21
Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature (1999) 3.16
Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev (1998) 3.16
Generalized potential of adult neural stem cells. Science (2000) 3.15
Preventing ventricular fibrillation by flattening cardiac restitution. Proc Natl Acad Sci U S A (2000) 3.15
OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell (2000) 3.12
Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature (1997) 3.12
Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (1995) 3.11
Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol (1989) 3.10
A Smad transcriptional corepressor. Cell (1999) 3.07
Oncogenes in solid human tumours. Nature (1982) 3.00
trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell (1991) 2.97
Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature (1992) 2.97
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science (1984) 2.97
Biochemical and immunological characterization of polyproteins coded for by the McDonough, Gardner-Arnstein, and Snyder-Theilen strains of feline sarcoma virus. J Virol (1980) 2.92
A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci U S A (1992) 2.92
Microsomal triglyceride transfer protein expression during mouse development. J Lipid Res (2000) 2.90
The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell (2001) 2.87
The TGF-beta family of growth and differentiation factors. Cell (1987) 2.86
Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nat Struct Biol (2001) 2.83
Origin and functional properties of the major gene product of the Snyder-Theilen strain of feline sarcoma virus. Proc Natl Acad Sci U S A (1980) 2.83
Nerve sprouting and sudden cardiac death. Circ Res (2000) 2.80
Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol (1995) 2.80
Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J (1997) 2.78
SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev (1998) 2.76
Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell (1991) 2.73
Regulation of cell adhesion receptors by transforming growth factor-beta. Concomitant regulation of integrins that share a common beta 1 subunit. J Biol Chem (1989) 2.71
p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A (1994) 2.63
The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem (1982) 2.62
Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature (1994) 2.61
Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol (1994) 2.59
Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev (1997) 2.59
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A (2001) 2.55
Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc Natl Acad Sci U S A (1982) 2.55
Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. Nat Genet (2000) 2.53
Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell (1993) 2.52
Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature (1997) 2.51
The TGF-alpha precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction. Cell (1989) 2.49